Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIme: Hepcidin as a Predictor of Iron Therapy Response in IBD
NCT05456932Phase 4Unknown
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric maltol, ferrous fumarate and Iron in iron deficiency anemia (IDA), sponsored by Leiden University Medical Center. Status: unknown.
02
Drugs
ferric maltolferrous fumarateIron
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05456932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456932.